Trials / Completed
CompletedNCT00738569
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- National Jewish Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether or not adding Raltegravir to a fully suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic inflammation and increase the t-lymphocyte memory cell pool.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raltegravir | Raltegravir 400 mg PO BID for 12 months |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2008-08-20
- Last updated
- 2021-01-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00738569. Inclusion in this directory is not an endorsement.